GLP1R and chronic kidney disease: The FLOW trial will be the first dedicated kidney outcome trial to evaluate whether the GLP1 receptor agonist semaglutide delays progression of kidney disease and reduces the risk of death from renal or cardiovascular disease in patients with T2DM and CKD (ClinicalTrials.gov Identifier: NCT03819153).